Two-stage framework for evaluating American Well’s next market moves
Today’s task, by and large, is to help American Well identify its next strategic marketing move among a number of options - the development of the “Team Edition” product, entering different markets along the value chain, and international expansion among them. Since this assignment feels particularly integrative (bringing together various lessons from previous classes), I’m going to do what I would perhaps do in a marketer’s position and create - and apply - a framework such that my decision making is less about intuition and more about deliberate judgment.
First and foremost, I have to make a strategic decision regarding whether to continue focusing on the buildout of the existing product or simultaneously expanding into a new product category. In order to do this, I would examine the existing product based on Roger’s Five Forces, thus deciding if the nascent brand would be sufficient to grow on its own/stand on its own feet, or if another product marketed in parallel would help it overcome deficiencies:
- Relative advantage: based on a B2B model, where the primary buyer is the insurer (payer) and the end user is the patient, I believe this provides a clear relative advantage over the existing system. It saves both payer and patient two things it greatly values - time and money - in exponential ways. Very high marks.
- Compatibility: this will be one of the company’s greatest challenges, as patients are not used to the idea of not seeing a doctor physically. Marketing spend should focus heavily on consumer education, both directly to the patient and providing consistent messaging materials through each of its client payers. Low marks.
- Complexity: it appears that the product is easy for consumers to use, and in fact resembles elements of the freelancer/sharing economy we see today by absorbing and effectively redistributing slack bandwidth (doctors waiting around while others experience high demand). High marks (meaning low complexity)
- Trialibilaity: with almost no commitment from the patient, who will be responsible for the resulting utilization, there is high trainability; payers will have certain sunk costs related to the initial number of addressable lives they purchase, but a large portion of the investment is related to annual, recurring costs - which would disappear if they were to abandon the product. This also gets high marks.
- Observability: it is not immediately observable if you are tele-medicining, though word of mouth value may be high. People may “see” you “using” the existing system - attending the doctor’s office - but the existing system would not benefit from observability any more than American Well. Thus, moderate marks.
With this analysis in hand, I would immediately discard the idea of trying to expand into a new product at the moment. There are clear synergies between the two, but while the temptation of the firm is to expand quickly and ruthlessly, they risk overshooting their resources and overextending their brand by moving too far, too fast. I feel they should only engage in Team Edition if their core product is otherwise insufficient as a standalone, but this is clearly not the case. They should not enter the Team Edition product category.
Looking, then, at market opportunities, I would be most concerned with the following elements:
Credibility: since Compatibility with existing processes is markedly low, our brand is very new, and the brand is attempting to change major elements of consumer behavior, I think that the brand should focus heavily on what markets will bolster its credibility among consumers. Not least because medical care is involved, Trust - by patients, payers, and providers alike - will be a bedrock element of building this brand.
Lateralism: having already begun to convince insurers of American Well’s value proposition, moves into new markets should happen in ways that are already closely connected to existing customer base (payers). This way, we avoid marketing mission creep and brand dilution, keeping our embodied value and exchange values alike consistent and ensuring curation of a brand that does not yet have substantial brand equity.
End User Awareness Development: I would want to see the “franchise” built out in ways that get users interacting with the product more frequently in places where they would have traditionally accessed the existing healthcare delivery system. This will position the brand for future forays into DTC, which could be a much larger market (eventually).
Regulatory Complexity Avoidance: at this stage, it is about rapid growth; being burdened by trying to learn and navigate new regulatory regimes is incompatible with trying to reach scale quickly, for the time being. This effectively mollifies any international expansion for the time being.
Limited Stakeholder Resistance: since Compatibility is already low, American Well will want to limit the number of other stakeholders who might resist our entry until we are able to develop more brand influence and product inertia.
Thus, based on the other available options being considered - market entries into hospitals, retail clinics, or pharmacies, or international expansion, using these criteria I would opt for Market Entry into Hospitals. Retail clinics might increase end user awareness, but it would be the most likely to present resistance (since this may undermine parts of their revenue model, even if it provides other benefits and more effectively redistributes demand across the system). Hospitals would appear to be more dependent on insurers even than pharmacies - the latter which can subsidize its pharmacy revenues with other retail in-store - and they certainly command the most credibility between the three potential options. As indicated, international expansion right now is preemptive, as attempts to deal with regulation (already one of the most onerous regulatory frameworks globally) would distract from growth.